Difficulty: Medium
Average Score: 71%
Practice
All of the following statements regarding inhibitors of type III phosphodiesterase are true EXCEPT:
Correct answer
C
Rationale
Inhibitors of type III phosphodiesterase, such as milrinone, are commonly used in the management of heart failure. Let's break down the options to understand why each statement is either true or false.
A) The statement "They raise cAMP concentrations in cardiac myocytes" is true. Inhibitors of type III phosphodiesterase prevent the breakdown of cAMP, leading to increased levels of cAMP in cardiac myocytes, which results in positive inotropic effects.
B) The statement "They reduce afterload" is true. By increasing cAMP levels in vascular smooth muscle cells, these inhibitors cause vasodilation, which reduces systemic vascular resistance and afterload on the heart.
C) The statement "They show significant cross-tolerance with beta-receptor agonists" is false, making it the correct answer. Unlike beta-receptor agonists, inhibitors of type III phosphodiesterase do not exhibit significant cross-tolerance. This distinction is important in clinical practice when managing patients with heart failure.
D) The statement "They are associated with a significant risk for cardiac arrhythmias" is false. While these medications can have side effects such as hypotension and ventricular arrhythmias, they are not specifically associated with a significant risk for cardiac arrhythmias.
Educational Context:
Understanding the mechanisms of action and pharmacological properties of medications used in heart failure management is crucial for healthcare professionals. Inhibitors of type III phosphodiesterase play a significant role in improving cardiac function in heart failure patients. Knowing the effects, side effects, and differences between various drug classes helps practitioners make informed decisions when selecting and adjusting treatment regimens for their patients.
A) The statement "They raise cAMP concentrations in cardiac myocytes" is true. Inhibitors of type III phosphodiesterase prevent the breakdown of cAMP, leading to increased levels of cAMP in cardiac myocytes, which results in positive inotropic effects.
B) The statement "They reduce afterload" is true. By increasing cAMP levels in vascular smooth muscle cells, these inhibitors cause vasodilation, which reduces systemic vascular resistance and afterload on the heart.
C) The statement "They show significant cross-tolerance with beta-receptor agonists" is false, making it the correct answer. Unlike beta-receptor agonists, inhibitors of type III phosphodiesterase do not exhibit significant cross-tolerance. This distinction is important in clinical practice when managing patients with heart failure.
D) The statement "They are associated with a significant risk for cardiac arrhythmias" is false. While these medications can have side effects such as hypotension and ventricular arrhythmias, they are not specifically associated with a significant risk for cardiac arrhythmias.
Educational Context:
Understanding the mechanisms of action and pharmacological properties of medications used in heart failure management is crucial for healthcare professionals. Inhibitors of type III phosphodiesterase play a significant role in improving cardiac function in heart failure patients. Knowing the effects, side effects, and differences between various drug classes helps practitioners make informed decisions when selecting and adjusting treatment regimens for their patients.